Through the collaboration, Protagen and UCSF intend to provide further insight into utilizing immune system profiling to predict treatment response and monitor prostate cancer patients for irAEs, specifically, a so-called cold tumor that it is difficult to target with immuno-therapies.
UCSF is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.
It includes top ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, transitional and population sciences; and a preeminent biomedical research enterprise.
Protagen is dedicated to the development of precision diagnostic tools that aid successful therapeutic development and facilitate improved treatment strategies in the areas of immuno-oncology and autoimmune disease.
The company is currently using SeroTag to uncover the power of autoantibodies as biomarkers for irAE and therapeutic response prediction in cancer, which will enable the development of safer, more effective immunotherapies.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial